Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603392's ROE % is ranked better than 75.42% of 1249
companies
in the Biotechnology industry
Industry Median: -38.61
vs SHSE:603392: -3.23
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Beijing Wantai Biological Pharmacy Enterprise Co ROE % Related Terms
Beijing Wantai Biological Pharmacy Enterprise Co ROE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Wantai Biological Pharmacy Enterprise Co ROE % Chart
Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Wantai Biological Pharmacy Enterprise Co ROE % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a ROE % of -1.45% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. According to the industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #307 out of 1249 companies in the Biotechnology industry, placing it in the top 24.6%.
Is Beijing Wantai Biological Pharmacy Enterprise Co's ROE % too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current ROE % is -1.45%. Based on the distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #307 out of 1249 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Beijing Wantai Biological Pharmacy Enterprise Co ranks #307 out of 1249 companies for ROE %. This places Beijing Wantai Biological Pharmacy Enterprise Co in the top 25% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. Beijing Wantai Biological Pharmacy Enterprise Co's current ROE % is -1.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥42.09, compared to a current price of ¥29.20 — trading 30.6% below its estimated fair value. The current ROE % is -1.45%. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current ROE % is -1.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued.
The current stock price of ¥29.20 is trading 30.6% below its estimated GF Value™ of ¥42.09.
GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.
Key valuation signals for SHSE:603392:
ROE %: -1.45%
GF Value™: ¥42.09 vs. price of ¥29.20 (30.6% below fair value)
No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Wantai Biological Pharmacy Enterprise Co Business Description
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
53GF Score
Get the complete analysis for SHSE:603392
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603392 has been successfully added to your 
